Company

History

2011~2016

  • 201606

    Constructed Samyang Discovery Center

  • 201509

    The anti-cancer drug, Protezomib® Injection was approved

  •  08

    API Bortezomib trimer was approved

  •  07

    Re-designated as an innovative pharmaceutical company by the Ministry of Health and Welfare

  •  05

    The anti-cancer drug Pemed®S Injection(liquid) was approved

  •  03

    The hemostat SurgiGuard® Fabric, Fibrillar, Non-woven was approved

  • 201412

    ORC Adhesion Barrier Interguard® was approved

  •  09

    The hemostat SurgiGuard® Original was approved

  • 201307

    Samyang Biopharm and Samyang Genex Bio merged into one company

  •  06

    Drug-contained suture (Neosorb® Plus) was approved

  •  05

    Launched the painkiller Fentaderm® patch

  •  04

    Launched the oral-disintegrating drug antinauseant Imestop®

  •  03

    Launched the anticancer drug Nanoxel® M Injection

  • 201212

    Hit 100,000 km annual surgical suture sales (in terms of bulk volume)

  •   

    Launched the anticancer adjuvant Zolenic® Injection

  •   

    The anticancer drug Nanoxel®M Injection was approved

  •  08

    Launched the surgical sutures Monsnorb® Plus and Monofast® Plus

  •   

    The antinauseant Emestop® Injection was approved

  •  06

    Designated as an innovative pharmaceutical company by the Ministry of Health and Welfare

  •  04

    Samyang Genex spun off Samyang Genex Bio (physical division)

  • 201111

    Samyang Group transformed into a holding company structure Samyang Biopharmaceuticals Corporation established

  •  03

    Suture Neosorb plus(For export) approved

  •  01

    Samyang Tulobuterol patch(For export) approved

2000~2010

  • 201006

    Launched Neosorb Plus (antibacterial absorbable suture)

  •  01

    Iran GMP certification for pharmaceuticals received

  • 200909

    Launched Monolene (Polypropylene suture)

  •  07

    Genexol-PM approved in India

  •  06

    Genexol-PM approved in Vietnam

  •  05

    Genexol-PM approved in Philippine

  •  01

    Genexol approved in Serbia

  • 200811

    Docetaxel-PM received IND approval

  •  07

    Capsaicin plaster received IND approval

  • 200702

    Genexol-PM wins Korea New Drug Award

  •  02

    GENEXOL-PM™ (next generation anti-cancer agent using Paclitaxel, injection) marketed in Korea

  • 200612

    Genexol-PM wins Health industry & technology award

  •  09

    Genexol-PM injection was selected as 2006 supported overseas technology transfer business by KHIDI

  •  09

    Launched the suture Neosorbil

  •  05

    Genexol-PM selected as 2006 biotechnology development business

  • 200512

    Launched Nicostop Troch

  •  06

    Launched the Monofast suture

  • 200205

    Pharmaceutical research corporation established in Utah Samyang Research Corporation (SRC)

  •  03

    Poorly water-soluble drug-contained system won Patent Technology
    Ji Seok-yeong Award (KIPO, Choong-Ang Ilbo)

  • 200103

    Genexol Injection certified as effective in breast cancer treatment

  • 200008

    Surgisorb and BioMesh acquire CE mark

1992~1999

  • 199912

    Medical devices acquire ISO 9001 & EN 46001 certification

  •  08

    KGMP certification for medical device received

  • 199705

    Trisorb wins Jang Young Shil Award

  • 199611

    KGMP certification for pharmaceuticals received

  •  07

    Completed the construction of Daedeok Pharmaceutical Plant

  • 199410

    Medical suture products win patented technology award

  • 199310

    Medical suture products granted the Korea Good Technology mark

  • 199209

    Pharmaceutical Research Center established